Developing radionuclide PARP inhibitors
Interviewee/Contributor
Greg Mullen
Organisation
Theragnostics Ltd
Research Directory
The linker matters in antibody-drug conjugates
Interviewee/ContributorPhilipp SpycherOrganisationAraris Biotech AGReal world evidence is changing regulatory policy
Interviewee/ContributorMarie Manley and Zina ChatzidimitriadouOrganisationSidley Austin LLPThe hunt for the perfect tumour-associated antigen
Interviewee/ContributorErik MantingOrganisationDCPrime BVNew treatments for amyotrophic lateral sclerosis
Interviewee/ContributorPeter CharlishOrganisationMedNousUsing wastewater surveillance to control Covid-19
Interviewee/ContributorGerard BrandonOrganisationDeepVerge PlcTransatlantic partnerships in life science
Interviewee/ContributorOlivier LitzkaOrganisationAndera PartnersThe role of antibodies in Covid-19 treatment
Interviewee/ContributorPeter CharlishOrganisationMedNousOncology approvals are on an upward trend
Interviewee/ContributorBruno PagliaraOrganisationMedNousFinding a link between the microbiome and disease
Interviewee/ContributorSteff TaelmanOrganisationBioLizard NV